38564875|t|Catatonia in patients with dementia: A descriptive study of clinical profiles and treatment response.
38564875|a|BACKGROUND: Catatonia is a highly prevalent syndrome in patients presenting with major neurocognitive disorders (dementia). In this study, we aim to provide a comprehensive description of the clinical and therapeutic aspects of catatonia in patients with dementia. METHOD: This descriptive study, conducted between September 2015 and June 2022, collected data from 25 patients diagnosed with dementia, out of 143 patients treated for catatonia in our specialized psychiatry department. We collected sociodemographic, clinical and treatment data for each patient. RESULTS: Dementia patients constituted 17% of the catatonic cases. Predominantly female, the cohort had a mean age of 65. Diagnoses included Alzheimer's (4 patients, 17%) and Parkinson's (1 patient, 4%) diseases, Lewy body dementia (5 patients, 21%), vascular dementia (4 patients, 17%) and frontotemporal lobar degeneration (10 patients, 41%). The mean Bush-Francis Catatonia Rating Scale score upon admission was 20/69. Overall, complete remission of catatonia was achieved in 75% of patients (n=18), with only 13% (n=3) responding to lorazepam alone, while others required additional interventions such as electroconvulsive therapy (ECT) and/or amantadine. Vascular dementia was predominantly observed in cases resistant to treatment. CONCLUSION: The findings indicate a frequent co-occurrence of catatonia and dementia, highlighting treatability yet suggesting a potential for resistance to lorazepam, which varies by dementia diagnosis. Investigating the mechanisms underlying this resistance and the variability in treatment response is crucial for developing more precise therapeutic strategies.
38564875	0	9	Catatonia	Disease	MESH:D002389
38564875	13	21	patients	Species	9606
38564875	27	35	dementia	Disease	MESH:D003704
38564875	114	123	Catatonia	Disease	MESH:D002389
38564875	158	166	patients	Species	9606
38564875	189	213	neurocognitive disorders	Disease	MESH:D019965
38564875	215	223	dementia	Disease	MESH:D003704
38564875	330	339	catatonia	Disease	MESH:D002389
38564875	343	351	patients	Species	9606
38564875	357	365	dementia	Disease	MESH:D003704
38564875	470	478	patients	Species	9606
38564875	494	502	dementia	Disease	MESH:D003704
38564875	515	523	patients	Species	9606
38564875	536	545	catatonia	Disease	MESH:D002389
38564875	656	663	patient	Species	9606
38564875	674	682	Dementia	Disease	MESH:D003704
38564875	683	691	patients	Species	9606
38564875	715	724	catatonic	Disease	MESH:D012560
38564875	806	817	Alzheimer's	Disease	MESH:D000544
38564875	821	829	patients	Species	9606
38564875	840	851	Parkinson's	Disease	MESH:D010300
38564875	855	862	patient	Species	9606
38564875	878	896	Lewy body dementia	Disease	MESH:D020961
38564875	900	908	patients	Species	9606
38564875	916	933	vascular dementia	Disease	MESH:D015140
38564875	937	945	patients	Species	9606
38564875	956	989	frontotemporal lobar degeneration	Disease	MESH:D057174
38564875	994	1002	patients	Species	9606
38564875	1032	1041	Catatonia	Disease	MESH:D002389
38564875	1118	1127	catatonia	Disease	MESH:D002389
38564875	1151	1159	patients	Species	9606
38564875	1202	1211	lorazepam	Chemical	MESH:D008140
38564875	1313	1323	amantadine	Chemical	MESH:D000547
38564875	1325	1342	Vascular dementia	Disease	MESH:D015140
38564875	1465	1474	catatonia	Disease	MESH:D002389
38564875	1479	1487	dementia	Disease	MESH:D003704
38564875	1560	1569	lorazepam	Chemical	MESH:D008140
38564875	1587	1595	dementia	Disease	MESH:D003704
38564875	Negative_Correlation	MESH:D000547	MESH:D002389
38564875	Negative_Correlation	MESH:D008140	MESH:D002389

